Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 389
Filter
1.
J Immunol ; 208(2): 257-266, 2022 01 15.
Article in English | MEDLINE | ID: mdl-35017215

ABSTRACT

This Brief Review delves into B cell responses in the context of allergy. The primary contribution of B cells to allergy is the production of IgE, the Ab isotype that triggers immediate hypersensitivity reactions through the release of mediators from mast cells and basophils. B cells may also have protective roles in allergy, such as through the production of IgG or as regulatory B cells. In this review, I focus on the basic principles of B cell differentiation and discuss features relevant to allergic immune responses. In particular, I discuss: (1) class-switch recombination; (2) plasma cell differentiation; (3) germinal centers and affinity maturation; and (4) memory B cells and recall responses, with an emphasis on IgE, IgG1, and IgG4. I also consider how B cells may contribute to allergic responses independent of Ab production-for example, by serving as APCs.


Subject(s)
B-Lymphocytes/immunology , Cell Differentiation/immunology , Hypersensitivity, Immediate/immunology , Immunoglobulin Class Switching/immunology , Immunoglobulin E/immunology , B-Lymphocytes, Regulatory/immunology , Basophils/immunology , Germinal Center/immunology , Humans , Hypersensitivity, Immediate/pathology , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Immunologic Memory/immunology , Lymphocyte Activation/immunology , Mast Cells/immunology , Memory B Cells/immunology , Plasma Cells/cytology , Plasma Cells/immunology
2.
J Immunol ; 208(2): 267-277, 2022 01 15.
Article in English | MEDLINE | ID: mdl-35017216

ABSTRACT

Alpha-gal syndrome (AGS) describes a collection of symptoms associated with IgE-mediated hypersensitivity responses to the glycan galactose-alpha-1,3-galactose (alpha-gal). Individuals with AGS develop delayed hypersensitivity reactions, with symptoms occurring >2 h after consuming mammalian ("red") meat and other mammal-derived food products. The mechanisms of pathogenesis driving this paradigm-breaking food allergy are not fully understood. We review the role of tick bites in the development of alpha-gal-specific IgE and highlight innate and adaptive immune cells possibly involved in alpha-gal sensitization. We discuss the impact of alpha-gal glycosylation on digestion and metabolism of alpha-gal glycolipids and glycoproteins, and the implications for basophil and mast cell activation and mediator release that generate allergic symptoms in AGS.


Subject(s)
Food Hypersensitivity/immunology , Food Hypersensitivity/physiopathology , Immunoglobulin E/immunology , Tick Bites/physiopathology , Animals , Bacteria/immunology , Disease Models, Animal , Glycolipids/metabolism , Glycoproteins/metabolism , Humans , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/pathology , Lymphocytes/immunology , Mice , Red Meat/adverse effects , Tick Bites/microbiology
3.
Chem Biol Interact ; 351: 109751, 2022 Jan 05.
Article in English | MEDLINE | ID: mdl-34826398

ABSTRACT

p-phenylenediamine (PPD) is a common component of hair dye known to induce immediate allergy, even acute dermatitis and contact dermatitis. MAS-related G protein coupled receptor-X2 (MRGPRX2) in mast cells (MCs) mediates small molecular substances-induced pseudo-allergic reactions. However, the role of MRGPRX2 in PPD-induced immediate contact allergy needs further exploration. The aim of this study was to investigate whether PPD activates MCs via MRGPRX2 and induces immediate allergies that contribute to contact dermatitis. Wild-type (WT) and kitw-sh/w-sh mice (MUT) were treated with PPD to observe local inflammation and MC degranulation in vivo. The release of inflammatory mediators was measured in vitro. Histamine 1 receptor (H1R)-/- mice were used to analyze itch type. PPD caused immediate contact allergy in WT mice, induced scratching, and local inflammatory reactions, while exhibiting minimal effects on MUT mice. PPD did not induce histamine release, but induced significant tryptase release in vivo and in vitro. PPD activated MRGPRX2 to induce MC degranulation in vitro. PPD caused immediate contact allergy in WT mice, induced scratching and local inflammatory reactions, while exhibited minimal effect on MUT mice. PPD did not induce histamine release, while induced significant tryptase release in vivo and in vitro. PPD induced immediate contact allergy by MCs activation via MRGPRX2 and lead to tryptase release. The scratching times showed no significant difference in WT mice or H1R-/- mice, which indicated PPD caused non-histaminergic itch. The results showed that PPD activated MCs via MRGPRX2 and induced immediate contact allergy, leading to the release of tryptase without monoamine release, which might induce non-histaminergic itch.


Subject(s)
Dermatitis, Contact/etiology , Hypersensitivity, Immediate/etiology , Phenylenediamines/pharmacology , Receptors, G-Protein-Coupled/metabolism , Animals , Cell Line , Dermatitis, Contact/metabolism , Dermatitis, Contact/pathology , Gene Knockdown Techniques , Hypersensitivity, Immediate/metabolism , Hypersensitivity, Immediate/pathology , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/pathology , Male , Mast Cells/drug effects , Mast Cells/metabolism , Mice, Inbred C57BL , Pruritus/chemically induced , Pruritus/enzymology , Pruritus/metabolism , Receptors, G-Protein-Coupled/genetics , Skin/drug effects , Skin/metabolism , Skin/pathology , Tryptases/metabolism
5.
Sci Rep ; 11(1): 13823, 2021 07 05.
Article in English | MEDLINE | ID: mdl-34226570

ABSTRACT

The prevalence of asthma is considerably high among women of childbearing age. Most asthmatic women also often have other atopic disorders. Therefore, the differentiation between patients with atopic diseases without asthma and asthmatics with coexisting diseases is essential to avoid underdiagnosis of asthma and to design strategies to reduce symptom severity and improve quality of life of patients. Hence, we aimed for the first time to conduct an analysis of volatile organic compounds in exhaled breath of women of childbearing age as a new approach to discriminate between asthmatics with other coexisting atopic diseases and non-asthmatics (with or without atopic diseases), which could be a helpful tool for more accurate asthma detection and monitoring using a noninvasive technique in the near future. In this study, exhaled air samples of 336 women (training set (n = 211) and validation set (n = 125)) were collected and analyzed by thermal desorption coupled with gas chromatography-mass spectrometry. ASCA (ANOVA (analysis of variance) simultaneous component analysis) and LASSO + LS (least absolute shrinkage and selection operator + logistic regression) were employed for data analysis. Fifteen statistically significant models (p-value < 0.05 in permutation tests) that discriminated asthma with other coexisting atopic diseases in women of childbearing age were generated. Acetone, 2-ethyl-1-hexanol and a tetrahydroisoquinoline derivative were selected as discriminants of asthma with other coexisting atopic diseases. In addition, carbon disulfide, a tetrahydroisoquinoline derivative, 2-ethyl-1-hexanol and decane discriminated asthma disease among patients with other atopic disorders. Results of this study indicate that refined metabolomic analysis of exhaled breath allows asthma with other coexisting atopic diseases discrimination in women of reproductive age.


Subject(s)
Asthma/diagnosis , Exhalation , Hypersensitivity, Immediate/diagnosis , Volatile Organic Compounds/isolation & purification , Adult , Asthma/metabolism , Asthma/pathology , Breath Tests , Diagnosis, Differential , Female , Gas Chromatography-Mass Spectrometry , Humans , Hypersensitivity, Immediate/metabolism , Hypersensitivity, Immediate/pathology , Male , Quality of Life , Volatile Organic Compounds/metabolism
6.
Chest ; 158(5): 1841-1856, 2020 11.
Article in English | MEDLINE | ID: mdl-32569636

ABSTRACT

BACKGROUND: Nasal (airway) epithelial methylation profiles have been associated with asthma, but the effects of such profiles on expression of distant cis-genes are largely unknown. RESEARCH QUESTION: To identify genes whose expression is associated with proximal and distal CpG probes (within 1 Mb), and to assess whether and how such genes are differentially expressed in atopic asthma. STUDY DESIGN AND METHODS: Genome-wide expression quantitative trait methylation (eQTM) analysis in nasal epithelium from Puerto Rican subjects (aged 9-20 years) with (n = 219) and without (n = 236) asthma. After the eQTM analysis, a Gene Ontology Enrichment analysis was conducted for the top 500 eQTM genes, and mediation analyses were performed to identify paths from DNA methylation to atopic asthma through gene expression. Asthma was defined as physician-diagnosed asthma and wheeze in the previous year, and atopy was defined as at least one positive IgE to allergens. Atopic asthma was defined as the presence of both atopy and asthma. RESULTS: We identified 16,867 significant methylation-gene expression pairs (false-discovery rate-adjusted P < .01) in nasal epithelium from study participants. Most eQTM methylation probes were distant (average distance, ∼378 kb) from their target genes, and also more likely to be located in enhancer regions of their target genes in lung tissue than control probes. The top 500 eQTM genes were enriched in pathways for immune processes and epithelial integrity and were more likely to have been previously identified as differentially expressed in atopic asthma. In a mediation analysis, we identified 5,934 paths through which methylation markers could affect atopic asthma through gene expression in nasal epithelium. INTERPRETATION: Previous epigenome-wide association studies of asthma have estimated the effects of DNA methylation markers on expression of nearby genes in airway epithelium. Our findings suggest that distant epigenetic regulation of gene expression in airway epithelium plays a role in atopic asthma.


Subject(s)
Asthma , DNA Methylation/genetics , Hypersensitivity, Immediate , Nasal Mucosa , Adolescent , Allergens/classification , Asthma/diagnosis , Asthma/epidemiology , Asthma/genetics , Asthma/immunology , Case-Control Studies , Child , Epigenome , Gene Expression Profiling , Gene Expression Regulation , Gene Ontology , Genome-Wide Association Study , Humans , Hypersensitivity, Immediate/blood , Hypersensitivity, Immediate/epidemiology , Hypersensitivity, Immediate/genetics , Hypersensitivity, Immediate/pathology , Immunoglobulin E/analysis , Nasal Mucosa/immunology , Nasal Mucosa/pathology , Puerto Rico/epidemiology , Young Adult
7.
Curr Protein Pept Sci ; 21(8): 831-841, 2020.
Article in English | MEDLINE | ID: mdl-32392111

ABSTRACT

With an increase in atopic cases and owing to a significant role of mast cells in type I hypersensitivity, a therapeutic need to inhibit degranulation of mast cells has risen. Mast cells are notorious for IgE-mediated allergic response. Advancements have allowed researchers to improve clinical outcomes of already available therapies. Engineered peptides and antibodies can be easily manipulated to attain desired characteristics as per the biological environment. A number of these molecules are designed to target mast cells in order to regulate the release of histamine and other mediators, thereby controlling type I hypersensitivity response. The aim of this review paper is to highlight some of the significant molecules designed for the purpose.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Desensitization, Immunologic/methods , Hypersensitivity, Immediate/therapy , Immunosuppressive Agents/therapeutic use , Mast Cells/drug effects , Protein Engineering/methods , Adrenal Cortex Hormones/therapeutic use , Animals , Cell Degranulation/drug effects , Cell Degranulation/immunology , Gene Expression , Histamine/biosynthesis , Histamine/immunology , Histamine Antagonists/therapeutic use , Humans , Hypersensitivity, Immediate/genetics , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/pathology , Immunoglobulin E/biosynthesis , Mast Cells/immunology , Mast Cells/pathology , Protein Kinase Inhibitors/therapeutic use , Receptors, Fc/genetics , Receptors, Fc/immunology
10.
Clin Exp Allergy ; 49(5): 644-654, 2019 05.
Article in English | MEDLINE | ID: mdl-30689261

ABSTRACT

BACKGROUND: The immunopathogenesis of severe asthma has been associated with an inefficient regulatory response. There are a few studies about the CD4 T cells profile among individuals with severe asthma refractory to treatment. OBJECTIVE: To evaluate the CD4 T lymphocyte profile from individuals with severe asthma according to their response to treatment, relating to their atopy status and age of asthma onset. METHODS: We evaluated nineteen individuals with severe asthma refractory to treatment (SAR), 21 with well-controlled or partly controlled severe asthma (CSA) and 23 with mild-to-moderate asthma (MMA). Lymphocytes were obtained from PBMC, and the frequency of expression of different molecules in this population was assessed using the flow cytometry. RESULTS: We observed the frequency of CD4+ IFN-γ+ T cells was higher in atopic individuals with SAR than with CSA. In addition, among the atopic and early-onset asthma (EOA), the frequency of CD4+ CTLA-4+ T cells was lower in the SAR group than the CSA group. In relation to non-atopic and late-onset asthma (LOA) phenotypes, we noted the frequency of CD4+ FoxP3+ T cells was lower in individuals with SAR than with CSA. We also observed among the LOA patients, the frequency of CD4+ TGF-ß+ T cells was decreased in SAR group than the in CSA group. CONCLUSION AND CLINICAL RELEVANCE: Our data suggest that refractoriness to treatment in asthma is associated with a lower expression of distinct regulatory molecules by CD4 T cells between those who are atopic and have EOA and those who are non-atopic and have LOA. Thus, these results may contribute to the identification of new regulatory strategies to treat asthma according to their phenotypes.


Subject(s)
Asthma/immunology , Asthma/metabolism , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Immunomodulation , Adult , Age of Onset , Asthma/diagnosis , Biomarkers , CTLA-4 Antigen/metabolism , Cytokines/metabolism , Female , Flow Cytometry , Humans , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/metabolism , Hypersensitivity, Immediate/pathology , Immunoglobulin E/immunology , Immunophenotyping , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Respiratory Function Tests , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Vitamin D/metabolism
11.
In Vivo ; 33(1): 53-55, 2019.
Article in English | MEDLINE | ID: mdl-30587602

ABSTRACT

BACKGROUND/AIM: We investigated the inhibitory action of medium molecular weight heparinyl phenylalanine (MHF) on type I hypersensitivity in comparison with medium molecular weight heparinyl arginine (MHR). MATERIALS AND METHODS: MHF and MHR were synthesized from heparin (HE) to decrease the side-effect of HE based on its anticoagulant action and used in this study. RESULTS: MHF demonstrated a significant inhibitory action on 48-h homologous passive cutaneous anaphylaxis in rats. Although MHF did not affect the death of mice injected with a lethal dose of histamine, it significantly prolonged the survival time of mice administered a lethal dose of compound 48/80. On the other hand, MHR did not inhibit type I hypersensitivity. CONCLUSION: The inhibitory action of MHF on the type I allergic reaction was due to a reduction or delay in histamine release from mast cells. MHF may be a potent anti-allergic agent.


Subject(s)
Anticoagulants/administration & dosage , Histamine/toxicity , Hypersensitivity, Immediate/drug therapy , Phenylalanine/administration & dosage , Anaphylaxis/blood , Anaphylaxis/drug therapy , Anaphylaxis/pathology , Animals , Anticoagulants/chemical synthesis , Anticoagulants/chemistry , Arginine/administration & dosage , Arginine/chemical synthesis , Arginine/chemistry , Disease Models, Animal , Heparin/chemical synthesis , Heparin/chemistry , Hypersensitivity, Immediate/blood , Hypersensitivity, Immediate/pathology , Male , Mast Cells/drug effects , Mice , Molecular Weight , Phenylalanine/chemical synthesis , Phenylalanine/chemistry , Rats
12.
Front Immunol ; 9: 2763, 2018.
Article in English | MEDLINE | ID: mdl-30534130

ABSTRACT

Eosinophils are an enigmatic white blood cell, whose immune functions are still under intense investigation. Classically, the eosinophil was considered to fulfill a protective role against parasitic infections, primarily large multicellular helminths. Although eosinophils are predominantly associated with parasite infections, evidence of a role for eosinophils in mediating immunity against bacterial, viral, and fungal infections has been recently reported. Among the mechanisms by which eosinophils are proposed to exert their protective effects is the production of DNA-based extracellular traps (ETs). Remarkably, DNA serves a role that extends beyond its biochemical function in encoding RNA and protein sequences; it is also a highly effective substance for entrapment of bacteria and other extracellular pathogens, and serves as valuable scaffolding for antimicrobial mediators such as granule proteins from immune cells. Extracellular trap formation from eosinophils appears to fulfill an important immune response against extracellular pathogens, although overproduction of traps is evident in pathologies. Here, we discuss the discovery and characterization of eosinophil extracellular traps (EETs) in response to a variety of stimuli, and suggest a role for these structures in the pathogenesis of disease as well as the establishment of autoimmunity in chronic, unresolved inflammation.


Subject(s)
Crohn Disease/immunology , Eosinophils/immunology , Extracellular Traps/immunology , Helminthiasis , Hypersensitivity, Immediate/immunology , Pulmonary Disease, Chronic Obstructive/immunology , Animals , Chemokines/immunology , Crohn Disease/pathology , Cytoplasmic Granules/immunology , Eosinophils/pathology , Helminthiasis/immunology , Helminthiasis/pathology , Humans , Hypersensitivity, Immediate/pathology , Inflammation/immunology , Inflammation/pathology , Inflammation Mediators/immunology , Pulmonary Disease, Chronic Obstructive/pathology
13.
Front Immunol ; 9: 1805, 2018.
Article in English | MEDLINE | ID: mdl-30150981

ABSTRACT

Allergic (Th2high immunophenotype) asthmatics have a heightened susceptibility to common respiratory viral infections such as human rhinovirus. Evidence suggests that the innate interferon response is deficient in asthmatic/atopic individuals, while other studies show no differences in antiviral response pathways. Unsensitized and OVA-sensitized/challenged Th2high (BN rats) and Th2low immunophenotype (PVG rats) animals were inoculated intranasally with attenuated mengovirus (vMC0). Sensitized animals were exposed/unexposed during the acute viral response phase. Cellular and transcriptomic profiling was performed on bronchoalveolar lavage cells. In unsensitized PVG rats, vMC0 elicits a prototypical antiviral response (neutrophilic airways inflammation, upregulation of Th1/type I interferon-related pathways). In contrast, response to infection in the Th2high BN rats was associated with a radically altered intrinsic host response to respiratory viral infection, characterized by macrophage influx/Th2-associated pathways. In sensitized animals, response to virus infection alone was not altered compared to unsensitized animals. However, allergen exposure of sensitized animals during viral infection unleashes a notably exaggerated airways inflammatory response profile orders of magnitude higher in BN versus PVG rats despite similar viral loads. The co-exposure responses in the Th2high BN incorporated type I interferon/Th1, alternative macrophage activation/Th2 and Th17 signatures. Similar factors may underlie the hyper-susceptibility to infection-associated airways inflammation characteristic of the human Th2high immunophenotype.


Subject(s)
Hypersensitivity, Immediate/etiology , Hypersensitivity, Immediate/pathology , Immunity , Respiratory Tract Infections/complications , Respiratory Tract Infections/virology , Allergens/immunology , Animals , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Disease Models, Animal , Disease Susceptibility , Gene Expression Profiling , Rats , Severity of Illness Index , Viral Load
14.
J Clin Invest ; 128(7): 3116-3128, 2018 07 02.
Article in English | MEDLINE | ID: mdl-29911993

ABSTRACT

Protease-activated receptor 2 (PAR-2), an airway epithelial pattern recognition receptor (PRR), participates in the genesis of house dust mite-induced (HDM-induced) asthma. Here, we hypothesized that lung endothelial cells and proangiogenic hematopoietic progenitor cells (PACs) that express high levels of PAR-2 contribute to the initiation of atopic asthma. HDM extract (HDME) protease allergens were found deep in the airway mucosa and breaching the endothelial barrier. Lung endothelial cells and PACs released the Th2-promoting cytokines IL-1α and GM-CSF in response to HDME, and the endothelium had PAC-derived VEGF-C-dependent blood vessel sprouting. Blockade of the angiogenic response by inhibition of VEGF-C signaling lessened the development of inflammation and airway remodeling in the HDM model. Reconstitution of the bone marrow in WT mice with PAR-2-deficient bone marrow also reduced airway inflammation and remodeling. Adoptive transfer of PACs that had been exposed to HDME induced angiogenesis and Th2 inflammation with remodeling similar to that induced by allergen challenge. Our findings identify that lung endothelium and PACs in the airway sense allergen and elicit an angiogenic response that is central to the innate nonimmune origins of Th2 inflammation.


Subject(s)
Allergens/immunology , Asthma/etiology , Immunity, Innate , Lung/immunology , Airway Remodeling/immunology , Allergens/administration & dosage , Animals , Asthma/immunology , Cytokines/biosynthesis , Disease Models, Animal , Early Growth Response Transcription Factors/immunology , Endothelial Cells/immunology , Endothelial Cells/ultrastructure , Female , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/pathology , Humans , Hypersensitivity, Immediate/etiology , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/pathology , Kruppel-Like Transcription Factors/immunology , Lung/ultrastructure , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Electron, Transmission , Neovascularization, Pathologic , Pyroglyphidae/immunology , Receptor, PAR-2/deficiency , Receptor, PAR-2/genetics , Receptor, PAR-2/immunology , Th2 Cells/immunology , Vascular Endothelial Growth Factor Receptor-3/antagonists & inhibitors
15.
Eur Ann Allergy Clin Immunol ; 50(2): 66-71, 2018 03.
Article in English | MEDLINE | ID: mdl-29384109

ABSTRACT

Summary: Objective. To document the test results of patients referred to our clinic for testing with local anesthetics (LAs) in real life conditions and provide data related to the necessity of these tests. Methods. All consecutive subjects who were referred to be evaluated for LA allergy during a two-year follow up were included in the analysis. All subjects underwent skin prick / intradermal tests followed by a subcutaneous provocation test with the LAs tested. Results. A total of 228 subjects were included. The main referral reason was the presence of a history of drug hypersensitivity reaction (DHR) to drugs other than LAs (n = 128; 56%), whereas a history of LA allergy constituted the second most common referral reason (n = 64, 28.1%). In the majority of cases (n = 39; 60.9%), the culprit LA was not known by the patients. Asthma was the third most common referral reason, presented in 49 cases (21.5%). Ten cases had positivity to the tested LA in skin testing / challenges. Nine out of 10 patients had a history of DHR to drugs other than LA, whereas 5 of them had also a history of DHR to LA. Six of the 10 patients had a history of multiple DHR. None of the asthma patients without any DHR history were positive in the LA tests. Eight out of 10 cases who underwent skin testing / challenge with an alternative LA, tolerated the alternative LA. Conclusion. The most common referral reason for testing with LA was a history of DHR to drugs other than LAs, whereas asthma was the third most common referral reason. Patients with a history of multiple DHR may be considered for testing with LAs. Asthmatics and those with other allergic diseases without a history of drug / LA allergy do not need to be tested with LA.


Subject(s)
Anesthetics, Local/immunology , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/immunology , Hypersensitivity, Immediate/diagnosis , Adolescent , Adult , Anesthetics, Local/adverse effects , Asthma/chemically induced , Asthma/pathology , Female , Humans , Hypersensitivity, Immediate/chemically induced , Hypersensitivity, Immediate/pathology , Lidocaine/immunology , Male , Mepivacaine/immunology , Middle Aged , Prilocaine/immunology , Prospective Studies , Skin Tests , Young Adult
16.
Dis Markers ; 2017: 4159251, 2017.
Article in English | MEDLINE | ID: mdl-29038613

ABSTRACT

The aim of this study was to evaluate the cytological picture of nasal mucosa in children with atopic diseases and to determine the diagnostic value of the test for the diagnosis of atopic diseases. The study included 140 children from 4 months to 17 years old. Among children with a history of atopy, there were 30 children with atopic dermatitis, 30 children with asthma, and 46 children with allergic rhinitis. The control group consisted of 34 healthy children. The nasal scraping technique has been used to collect samples from the nasal cavity. The samples were evaluated under light microscope. Epithelial cells as well as infiltrating cells were assessed. The only statistically significant group of cells differentiating children with atopic disease and without atopy were eosinophils, which in children with atopy were significantly more common. Assuming a significant eosinophilia value of at least 5% of all cells in cytogram, the sensitivity of nasal cytology in allergic rhinitis was 52.2%, in asthma 33.3%, and in atopic dermatitis 13.3%. The specificity of the test in atopic diseases was 94.1%. It can be concluded that nasal cytology with eosinophilia assessment can be a useful tool for an early diagnosis of atopic disease in children.


Subject(s)
Hypersensitivity, Immediate/pathology , Nasal Mucosa/pathology , Adolescent , Case-Control Studies , Child , Child, Preschool , Female , Humans , Infant , Male
17.
Tissue Barriers ; 5(3): e1341367, 2017 07 03.
Article in English | MEDLINE | ID: mdl-28665760

ABSTRACT

Mucosal epithelium maintains tissue homeostasis through many processes, including epithelial barrier function, which separates the environment from the tissue. The barrier hypothesis of type 2 inflammatory disease postulates that epithelial and epidermal barrier dysfunction, which cause inappropriate exposure to the environment, can result in allergic sensitization and development of type 2 inflammatory disease. The restoration of barrier dysfunction once it's lost, or the prevention of barrier dysfunction, have the potential to be exciting new therapeutic strategies for the treatment of type 2 inflammatory disease. Neutrophil-derived Oncostatin M has been shown to be a potent disrupter of epithelial barrier function through the induction of epithelial-mesenchymal transition (EMT). This review will discuss these events and outline several points along this axis at which therapeutic intervention could be beneficial for the treatment of type 2 inflammatory diseases.


Subject(s)
Epithelial Cells/drug effects , Growth Inhibitors/pharmacology , Hypersensitivity, Immediate/drug therapy , Oncostatin M/pharmacology , Animals , Epithelial Cells/cytology , Epithelial Cells/metabolism , Epithelial-Mesenchymal Transition , Growth Inhibitors/therapeutic use , Humans , Hypersensitivity, Immediate/metabolism , Hypersensitivity, Immediate/pathology , Oncostatin M/therapeutic use
19.
Allergy ; 72(3): 473-482, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27624865

ABSTRACT

RATIONALE: Genetic polymorphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) have been associated with lung function decline and uPAR blood levels in asthma subjects. Preliminary studies have identified uPAR elevation in asthma; however, a definitive study regarding which clinical features of asthma uPAR may be driving is currently lacking. OBJECTIVES: We aimed to comprehensively determine the uPAR expression profile in asthma and control subjects utilizing bronchial biopsies and serum, and to relate uPAR expression to asthma clinical features. METHODS: uPAR levels were determined in control (n = 9) and asthmatic (n = 27) bronchial biopsies using immunohistochemistry, with a semi-quantitative score defining intensity in multiple cell types. Soluble-cleaved (sc) uPAR levels were determined in serum through ELISA in UK (cases n = 129; controls n = 39) and Dutch (cases n = 514; controls n = 96) cohorts. MEASUREMENTS AND MAIN RESULTS: In bronchial tissue, uPAR was elevated in inflammatory cells in the lamina propria (P = 0.0019), bronchial epithelial (P = 0.0002) and airway smooth muscle cells (P = 0.0352) of patients with asthma, with uPAR levels correlated between the cell types. No correlation with disease severity or asthma clinical features was identified. scuPAR serum levels were elevated in patients with asthma (1.5-fold; P = 0.0008), and we identified an association between high uPAR serum levels and severe, nonatopic disease. CONCLUSIONS: This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. The findings warrant further investigation and may provide a therapeutic opportunity for this refractory population.


Subject(s)
Asthma/diagnosis , Asthma/metabolism , Receptors, Urokinase Plasminogen Activator/metabolism , Respiratory Mucosa/metabolism , Asthma/blood , Asthma/etiology , Biomarkers , Biopsy , Bronchi/metabolism , Bronchi/pathology , Case-Control Studies , Female , Gene Expression , Humans , Hypersensitivity, Immediate/genetics , Hypersensitivity, Immediate/metabolism , Hypersensitivity, Immediate/pathology , Immunohistochemistry , Male , Phenotype , Receptors, Urokinase Plasminogen Activator/blood , Receptors, Urokinase Plasminogen Activator/genetics , Respiratory Function Tests , Respiratory Mucosa/immunology , Severity of Illness Index
20.
J Neurosci ; 36(47): 11929-11945, 2016 11 23.
Article in English | MEDLINE | ID: mdl-27881779

ABSTRACT

Allergic and atopic disorders have increased over the past few decades and have been associated with neuropsychiatric conditions, such as autism spectrum disorder and asthmatic amyotrophy. Myelitis presenting with neuropathic pain can occur in patients with atopic disorder; however, the relationship between allergic inflammation and neuropathic pain, and the underlying mechanism, remains to be established. We studied whether allergic inflammation affects the spinal nociceptive system. We found that mice with asthma, atopic dermatitis, or atopic diathesis had widespread and significantly more activated microglia and astroglia in the spinal cord than those without atopy, and displayed tactile allodynia. Microarray analysis of isolated microglia revealed a dysregulated phenotype showing upregulation of M1 macrophage markers and downregulation of M2 markers in atopic mice. Among the cell surface protein genes, endothelin receptor type B (EDNRB) was most upregulated. Immunohistochemical analysis revealed that EDNRB expression was enhanced in microglia and astroglia, whereas endothelin-1, an EDNRB ligand, was increased in serum, lungs, and epidermis of atopic mice. No EDNRA expression was found in the spinal cord. Expression of FBJ murine osteosarcoma viral oncogene homolog B was significantly higher in the dorsal horn neurons of asthma mice than nonatopic mice. The EDNRB antagonist BQ788 abolished glial and neural activation and allodynia. We found increased serum endothelin-1 in atopic patients with myelitis and neuropathic pain, and activation of spinal microglia and astroglia with EDNRB upregulation in an autopsied case. These results suggest that allergic inflammation induces diffuse glial activation, influencing the nociceptive system via the EDNRB pathway. SIGNIFICANCE STATEMENT: The prevalence of allergic disorders has markedly increased over the past few decades. Allergic disorders are associated with neuropsychiatric conditions; however, the relationship between allergic inflammation and CNS complications is unknown. A peculiar myelitis presenting with persistent neuropathic pain has been reported in patients with allergic disorders. We studied how atopy exerts substantial influence on the nociceptive system. We found that mice with allergic disorders had severe allodynia with activated astroglia and microglia, and showed marked upregulation of endothelin-1 (ET-1) receptor type B (EDNRB) in the spinal cord. A selective EDNRB antagonist prevented allodynia and glial activation. Our findings suggest a novel mechanism whereby atopy induces glial activation and neuropathic pain via an ET-1/EDNRB pathway.


Subject(s)
Hypersensitivity, Immediate/immunology , Neuralgia/immunology , Neuroglia/immunology , Nociception , Receptor, Endothelin B/immunology , Spinal Cord/immunology , Animals , Hypersensitivity, Immediate/complications , Hypersensitivity, Immediate/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neuralgia/etiology , Neuralgia/pathology , Neuroglia/pathology
SELECTION OF CITATIONS
SEARCH DETAIL